These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 11738739)

  • 1. Highly purified mutant E112K of cholera toxin elicits protective lung mucosal immunity to diphtheria toxin.
    Ohmura M; Yamamoto M; Kiyono H; Fujihashi K; Takeda Y; McGhee JR
    Vaccine; 2001 Dec; 20(5-6):756-62. PubMed ID: 11738739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel adjuvant for mucosal immunity to HIV-1 gp120 in nonhuman primates.
    Yoshino N; Lü FX; Fujihashi K; Hagiwara Y; Kataoka K; Lu D; Hirst L; Honda M; van Ginkel FW; Takeda Y; Miller CJ; Kiyono H; McGhee JR
    J Immunol; 2004 Dec; 173(11):6850-7. PubMed ID: 15557179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective mucosal immunity in aging is associated with functional CD4+ T cells in nasopharyngeal-associated lymphoreticular tissue.
    Hagiwara Y; McGhee JR; Fujihashi K; Kobayashi R; Yoshino N; Kataoka K; Etani Y; Kweon MN; Tamura S; Kurata T; Takeda Y; Kiyono H; Fujihashi K
    J Immunol; 2003 Feb; 170(4):1754-62. PubMed ID: 12574339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A.
    Yamamoto M; Briles DE; Yamamoto S; Ohmura M; Kiyono H; McGhee JR
    J Immunol; 1998 Oct; 161(8):4115-21. PubMed ID: 9780183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective immunity to Streptococcus mutans induced by nasal vaccination with surface protein antigen and mutant cholera toxin adjuvant.
    Saito M; Otake S; Ohmura M; Hirasawa M; Takada K; Mega J; Takahashi I; Kiyono H; McGhee JR; Takeda Y; Yamamoto M
    J Infect Dis; 2001 Mar; 183(5):823-6. PubMed ID: 11181162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nasally administered cholera toxin A-subunit acts as a mucosal adjuvant.
    Campos EA; Namikoshi J; Maeba S; Yamamoto M; Fukumoto M; Yamamoto H
    J Oral Sci; 2003 Mar; 45(1):25-31. PubMed ID: 12816361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Kozuka S; Taniguchi T; Matano K; Maeyama J; Komiya T; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 1999 Nov; 18(7-8):743-51. PubMed ID: 10547435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent nasal administrations of recombinant cholera toxin B subunit (rCTB)-containing tetanus and diphtheria toxoid vaccines induced antigen-specific serum and mucosal immune responses in the presence of anti-rCTB antibodies.
    Yasuda Y; Isaka M; Taniguchi T; Zhao Y; Matano K; Matsui H; Morokuma K; Maeyama J; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2003 Jun; 21(21-22):2954-63. PubMed ID: 12798639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeras of labile toxin one and cholera toxin retain mucosal adjuvanticity and direct Th cell subsets via their B subunit.
    Boyaka PN; Ohmura M; Fujihashi K; Koga T; Yamamoto M; Kweon MN; Takeda Y; Jackson RJ; Kiyono H; Yuki Y; McGhee JR
    J Immunol; 2003 Jan; 170(1):454-62. PubMed ID: 12496431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct effects on antigen-presenting cells and T lymphocytes explain the adjuvanticity of a nontoxic cholera toxin mutant.
    Yamamoto M; Kiyono H; Yamamoto S; Batanero E; Kweon MN; Otake S; Azuma M; Takeda Y; McGhee JR
    J Immunol; 1999 Jun; 162(12):7015-21. PubMed ID: 10358143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nasal cholera toxin elicits IL-5 and IL-5 receptor alpha-chain expressing B-1a B cells for innate mucosal IgA antibody responses.
    Kataoka K; Fujihashi K; Sekine S; Fukuiwa T; Kobayashi R; Suzuki H; Nagata H; Takatsu K; Shizukuishi S; McGhee JR; Fujihashi K
    J Immunol; 2007 May; 178(10):6058-65. PubMed ID: 17475830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity.
    Yamamoto S; Kiyono H; Yamamoto M; Imaoka K; Fujihashi K; Van Ginkel FW; Noda M; Takeda Y; McGhee JR
    Proc Natl Acad Sci U S A; 1997 May; 94(10):5267-72. PubMed ID: 9144226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Detection of LOS-specific antibody-secreting cells by ELISPOT assay].
    Jiao XA; Hirano T; Gu XX
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 May; 20(3):366-9. PubMed ID: 15193241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen.
    Boyaka PN; Tafaro A; Fischer R; Leppla SH; Fujihashi K; McGhee JR
    J Immunol; 2003 Jun; 170(11):5636-43. PubMed ID: 12759444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery.
    McNeela EA; O'Connor D; Jabbal-Gill I; Illum L; Davis SS; Pizza M; Peppoloni S; Rappuoli R; Mills KH
    Vaccine; 2000 Dec; 19(9-10):1188-98. PubMed ID: 11137256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic and mucosal immune responses of mice to aluminium-adsorbed or aluminium-non-adsorbed tetanus toxoid administered intranasally with recombinant cholera toxin B subunit.
    Isaka M; Yasuda Y; Kozuka S; Miura Y; Taniguchi T; Matano K; Goto N; Tochikubo K
    Vaccine; 1998 Oct; 16(17):1620-6. PubMed ID: 9713937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nasal immunization with the 40-kDa outer membrane protein of Porphyromonas gingivalis plus cholera toxin induces protective immunity in aged mice.
    Cai Y; Kurita-Ochiai T; Kobayashi R; Hashizume T; Yamamoto M
    J Oral Sci; 2013; 55(2):107-14. PubMed ID: 23748449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant cholera toxin B subunit (rCTB) as a mucosal adjuvant enhances induction of diphtheria and tetanus antitoxin antibodies in mice by intranasal administration with diphtheria-pertussis-tetanus (DPT) combination vaccine.
    Isaka M; Komiya T; Takahashi M; Yasuda Y; Taniguchi T; Zhao Y; Matano K; Matsui H; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2004 Aug; 22(23-24):3061-8. PubMed ID: 15297056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nasal immunization with E. coli verotoxin 1 (VT1)-B subunit and a nontoxic mutant of cholera toxin elicits serum neutralizing antibodies.
    Byun Y; Ohmura M; Fujihashi K; Yamamoto S; McGhee JR; Udaka S; Kiyono H; Takeda Y; Kohsaka T; Yuki Y
    Vaccine; 2001 Feb; 19(15-16):2061-70. PubMed ID: 11228378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.